Gene deletion of FDX1 confers resistance, whereas increased gene expression of FDX1 across 724 cancer cell lines is the top correlate with increased sensitivity to treatment with elesclomol, a mitochondria-targeted copper ionophore (477). This evidence concerns the gene FDX1 and cancer.